DDInter1174 DDInter1676
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Methotrexate {u} (Compound) resembles {v} (Compound) Raltitrexed
Methotrexate {u} (Compound) resembles {v} (Compound) Tetrahydrofolic acid
Methotrexate {u} (Compound) treats {v} (Disease) stomach cancer
Methotrexate {u} (Compound) binds {v} (Gene) SLC16A1
Methotrexate {u} (Compound) upregulates {v} (Gene) PDLIM1
Methotrexate {u} (Compound) is included by {v} (Pharmacologic Class) Folic Acid Metabolism Inhibitors
Methotrexate {u} (Compound) downregulates {v} (Gene) TMEM50A
Methotrexate {u} (Compound) causes {v} (Side Effect) Ecchymosis
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tromethamine
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Haloperidol
Methotrexate (Compound) resembles Raltitrexed (Compound)
Methotrexate (Compound) resembles Tetrahydrofolic acid (Compound)
Methotrexate (Compound) treats stomach cancer (Disease)
Methotrexate (Compound) binds SLC16A1 (Gene)
Methotrexate (Compound) upregulates PDLIM1 (Gene)
Methotrexate (Compound) is included by Folic Acid Metabolism Inhibitors (Pharmacologic Class)
Methotrexate (Compound) downregulates TMEM50A (Gene)
Methotrexate (Compound) causes Ecchymosis (Side Effect)
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Haloperidol